Brief by Shorts91 Newsdesk / 03:41pm on 16 Feb 2024,Friday Health & Wellness
UK scientists praise a "truly wonderful" drug for mesothelioma, an aggressive asbestos-linked cancer. The innovative treatment, combining ADI-PEG20 with chemotherapy, quadrupled three-year survival rates in a recent global clinical trial. Published in JAMA Oncology, the study involved patients from five countries and demonstrates a promising stride in oncology. Dr. Jyoti Mehta, an oncologist, expresses optimism, highlighting the potential for improved outcomes. While further studies are needed, this advancement offers hope for transforming the treatment landscape for asbestos-related cancers.
